2024-11-26 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance vs. S&P 500 (VOO):**

Johnson & Johnson (JNJ), a multinational healthcare company that manufactures medical devices, pharmaceuticals, and consumer packaged goods, significantly underperformed the S&P 500 (VOO) over the analyzed period.  The cumulative return for JNJ was 36.03%, while the S&P 500 achieved 127.58%. This resulted in a substantial lag of -91.55%. The relative divergence of -91.55% places JNJ in the lower 2.45% percentile of its historical performance relative to the S&P 500.

The provided CAGR data shows a generally declining trend in recent years (2017-2024), highlighting a decrease in growth compared to prior periods. While the alpha is generally positive (though weakening lately), indicating some outperformance against the market, it is dwarfed by the significant underperformance shown by the cumulative return difference. Beta values suggest a relatively lower correlation with the overall market compared to prior years.

**2. Recent Price Movement:**

* **Closing Price:** $155.15 (Last Market: $156.5)
* **5-Day Moving Average:** $154.31
* **20-Day Moving Average:** $166.36
* **60-Day Moving Average:** $161.14

The price is currently below all three moving averages, suggesting a bearish short-term trend.  The relatively small difference between the closing price and the 5-day MA suggests limited recent volatility. The distance to the 60-day MA implies a more significant downward move over the past two months.

**3. Technical Indicators and Relative Strength:**

* **RSI (39.91):** This indicates the stock is approaching oversold territory, suggesting potential for a short-term bounce.
* **PPO (0.05):** A near-zero PPO suggests a neutral momentum, with little indication of strong upward or downward pressure.
* **20-Day Relative Divergence (-3.73):** Shows a recent weakening in relative performance compared to the S&P 500.  The negative sign confirms the underperformance trend.
* **Expected Return (0.0%):**  The model projects no significant excess return relative to the S&P 500 over the long term (2+ years) with a buy-and-hold strategy at this point.  This aligns with the overall underperformance observed.  The $156.5 price does not appear to reflect a significant recent event (no mention of large upward or downward spikes).

**4. Recent Financial Performance:**

The provided EPS and revenue figures show some quarterly fluctuation but generally maintain a relatively consistent revenue stream. The significant increase in EPS in 2023-10-27 may require further investigation to understand the drivers behind this outlier.  A comparison with analyst expectations for the most recent quarter is crucial to assess whether the results exceeded or fell short of forecasts, which is not provided here.

**5. Financial Information Analysis (Revenue & Profitability & Capital & Profitability):**

The revenue figures reveal strong and consistent revenue generation over the past several quarters.  Profit margins are consistently high (around 70%), indicating robust profitability. The capital and profitability metrics (ROE) show some volatility, with a significant spike to 36.54% in 2023-09-30.  Again, more information is needed to interpret this exceptionally high ROE figure. Further investigation into these fluctuations and the factors driving them (e.g., one-time events) is needed.


**6. News and Recent Issues:**

* _Missing Information:_  The report requests analysis of recent news (within the past two days) from sources like Shacknews and Finbold and mentions of "Recent Market Outlook", "Analyst Opinions", and "Performance Highlights."  This information is not included in the provided data, preventing a complete assessment.

**7. Overall Analysis:**

JNJ has significantly underperformed the S&P 500 recently. While it shows historically strong revenue and profitability, recent performance has declined. Technical indicators suggest the stock may be oversold, but the overall trend is bearish.  The lack of recent news and analyst sentiment data prevents a definitive conclusion. A deeper dive into the outlier EPS and ROE figures is needed to fully assess the company's current health. The long-term outlook, considering the model's projected 0% excess return, seems uncertain without addressing the reasons for the recent underperformance relative to the market.  More granular financial data and news analysis is crucial to develop a fully informed investment decision.

**8.  Recommendations:**

Given the currently available data, it is impossible to make a clear recommendation. It's essential to gather more information, including recent news, analyst estimates, and a thorough review of the outlier data points (high ROE in Q3 2023 and elevated EPS in Q4 2023).  Once this additional data is obtained, a more complete analysis can determine if the current valuation reflects JNJ's underlying fundamentals and risk profile and whether the stock is currently under or overvalued compared to its projected future performance.  At this time, more research is absolutely necessary.
